title: The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes.
abstract: Epstein-Barr virus (EBV) transforms B lymphocytes through the expression of the latent viral proteins EBNA and latent membrane protein (LMP). Recently, it has become apparent that microRNAs (miRNAs) also contribute to EBV's oncogenic properties; recombinant EBVs that lack the BHRF1 miRNA cluster display a reduced ability to transform B lymphocytes in vitro. Furthermore, infected cells evince a marked upregulation of the EBNA genes. Using recombinant viruses that lack only one member of the cluster, we now show that all three BHRF1 miRNAs contribute to B-cell transformation. Recombinants that lacked miR-BHRF1-2 or miR-BHRF1-3 displayed enhanced EBNA expression initiated at the Cp and Wp promoters. Interestingly, we find that the deletion of miR-BHRF1-2 reduced the expression level of miR-BHRF1-3 and possibly that of miR-BHRF1-1, demonstrating that the expression of one miRNA can potentiate the expression of other miRNAs located in the same cluster. Therefore, the phenotypic traits of the miR-BHRF1-2 null mutant could result partly from reduced miR-BHRF1-1 and miR-BHRF1-3 expression levels. Nevertheless, using an miR-BHRF1-1 and miR-BHRF1-3 double mutant, we could directly assess and confirm the contribution of miR-BHRF1-2 to B-cell transformation. Furthermore, we found that the potentiating effect of miR-BHRF1-2 on miR-BHRF1-3 synthesis can be reproduced with simple expression plasmids, provided that both miRNAs are processed from the same transcript. Therefore, this enhancing effect does not result from an idiosyncrasy of the EBV genome but rather reflects a general property of these miRNAs. This study highlights the advantages of arranging the BHRF1 miRNAs in clusters: it allows the synchronous and synergistic expression of genetic elements that cooperate to transform their target cells.
authors.affiliation: German Cancer Research Center, ATV-F100, Heidelberg, Germany.
authors.forename: Regina
authors.initials: R
authors.lastname: Feederle
authors.forename: Janina
authors.initials: J
authors.lastname: Haar
authors.forename: Katharina
authors.initials: K
authors.lastname: Bernhardt
authors.forename: Sarah D
authors.initials: SD
authors.lastname: Linnstaedt
authors.forename: Helmut
authors.initials: H
authors.lastname: Bannert
authors.forename: Helge
authors.initials: H
authors.lastname: Lips
authors.forename: Bryan R
authors.initials: BR
authors.lastname: Cullen
authors.forename: Henri-Jacques
authors.initials: HJ
authors.lastname: Delecluse
mesh_terms: D001402:B-Lymphocytes / Q000821:virology*; D002460:Cell Line; D002472:Cell Transformation, Viral; D015967:Gene Expression Regulation, Viral; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000472:pathogenicity*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism*; D014764:Viral Proteins / Q000096:biosynthesis; D037521:Virulence Factors
chemical_list: C083278:BHRF1 protein, Human herpesvirus 4; D035683:MicroRNAs; D012367:RNA, Viral; D014764:Viral Proteins; D037521:Virulence Factors